[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aurinia Pharm Ord (AUPH)

Aurinia Pharm Ord (AUPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,105,215
  • Shares Outstanding, K 128,602
  • Annual Sales, $ 283,060 K
  • Annual Income, $ 287,200 K
  • EBIT $ 130 M
  • EBITDA $ 149 M
  • 60-Month Beta 1.41
  • Price/Sales 7.12
  • Price/Cash Flow 15.46
  • Price/Book 3.59

Options Overview Details

View History
  • Implied Volatility 48.71% (+1.31%)
  • Historical Volatility 39.33%
  • IV Percentile 41%
  • IV Rank 12.66%
  • IV High 186.40% on 02/13/26
  • IV Low 28.76% on 08/20/25
  • Expected Move (DTE 13) 0.88 (5.53%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 235
  • Volume Avg (30-Day) 1,266
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 36,083
  • Open Int (30-Day) 23,410
  • Expected Range 14.96 to 16.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.19
  • Number of Estimates 3
  • High Estimate $0.22
  • Low Estimate $0.17
  • Prior Year $0.16
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.40 +9.98%
on 05/07/26
16.70 -5.15%
on 06/05/26
-0.20 (-1.25%)
since 05/05/26
3-Month
13.81 +14.66%
on 03/30/26
16.88 -6.16%
on 04/23/26
+1.10 (+7.46%)
since 03/05/26
52-Week
7.28 +117.43%
on 07/02/25
16.88 -6.16%
on 04/23/26
+7.75 (+95.80%)
since 06/05/25

Most Recent Stories

More News
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress —

AUPH : 15.84 (-3.24%)
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences

Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer for...

AUPH : 15.84 (-3.24%)
Aurinia Reports Another Quarter Where LUPKYNIS Does the Talking

Barchart Research What to Expect from AUPH Earnings AUPH Generated May 8, 2026 Current Price $15.23 EPS Estimate $$0.19 Consensus Rating Moderate Buy Average Move 4.54% Aurinia Reports Another Quarter...

AUPH : 15.84 (-3.24%)
Aurinia: Q1 Earnings Snapshot

Aurinia: Q1 Earnings Snapshot

AUPH : 15.84 (-3.24%)
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial...

AUPH : 15.84 (-3.24%)
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has...

AUPH : 15.84 (-3.24%)
KZR : 7.29 (-0.95%)
Aurinia Announces Management Transition

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant...

AUPH : 15.84 (-3.24%)
Aurinia: Q4 Earnings Snapshot

Aurinia: Q4 Earnings Snapshot

AUPH : 15.84 (-3.24%)
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Full Year 2025 LUPKYNIS Sales Grew 25% Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million

AUPH : 15.84 (-3.24%)
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress...

AUPH : 15.84 (-3.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

See More

Key Turning Points

3rd Resistance Point 17.30
2nd Resistance Point 17.00
1st Resistance Point 16.42
Last Price 15.84
1st Support Level 15.54
2nd Support Level 15.24
3rd Support Level 14.66

See More

52-Week High 16.88
Last Price 15.84
Fibonacci 61.8% 13.21
Fibonacci 50% 12.08
Fibonacci 38.2% 10.95
52-Week Low 7.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.